BMS buys cancer start-up Flexus for up to $1.25bn
Bristol-Myers Squibb Co. paid $800mm up front for Flexus Biosciences Inc., a private cancer start-up that's also entitled to $450mm in development earn-outs.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com